Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio che valuta l'efficacia e la sicurezza dell'Etrasimod orale nel trattamento di partecipanti adulti con malattia di Crohn da moderatamente a gravemente attiva (CULTIVATE)

5 giugno 2026 aggiornato da: Pfizer

Uno studio multicentrico, randomizzato, in doppio cieco, a gruppi paralleli per valutare l'efficacia e la sicurezza di Etrasimod orale come terapia di induzione e mantenimento per la malattia di Crohn da moderatamente a gravemente attiva

Questo è uno studio di fase 2/3 che comprende 5 sottostudi progettati per valutare l'efficacia, la sicurezza e la tollerabilità di etrasimod orale come terapia in partecipanti adulti con malattia di Crohn (CD) da moderatamente a gravemente attiva che sono refrattari o intolleranti ad almeno 1 di le attuali terapie per la celiachia (ovvero corticosteroidi, immunosoppressori o farmaci biologici). La durata complessiva di questo studio è fino a 282 settimane, inclusi il periodo di screening di 28 giorni, il periodo di trattamento fino a 274 settimane (induzione, estensione o mantenimento e periodi di estensione a lungo termine) e il periodo di follow-up di 4 settimane Up Periodo per la valutazione della sicurezza.

Panoramica dello studio

Stato

Terminato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Questo studio comprende 5 sottostudi:

Sottostudio A - Fase 2: un sottostudio di Fase 2, randomizzato, in doppio cieco, per valutare la sicurezza, la tollerabilità e l'efficacia della terapia orale con etrasimod nei partecipanti con CD da moderata a grave che supporta la selezione di una dose di induzione e di mantenimento per la fase 3. Il sottostudio A è attualmente chiuso per l'iscrizione.

Sottostudio 1 - Fase 2: Un sottostudio di induzione di fase 2b randomizzato, in doppio cieco, controllato con placebo, a dosaggio variabile per valutare etrasimod come terapia di induzione e selezionare una o più dosi di induzione e di mantenimento per la valutazione continua nella fase 3. Il sottostudio 1 è stanno attualmente iscrivendo i partecipanti.

Sottostudio 2 - Induzione: un sottostudio di fase 3 randomizzato, in doppio cieco, controllato con placebo per valutare etrasimod come terapia di induzione.

Sottostudio 3 - Mantenimento: un sottostudio di Fase 3 randomizzato, in doppio cieco, controllato con placebo per valutare etrasimod come terapia di mantenimento. I partecipanti del Sottostudio 1 e del Sottostudio 2 saranno iscritti al Sottostudio 3.

Sottostudio 4 - Estensione a lungo termine: un sottostudio di estensione a lungo termine per i partecipanti che completano almeno 52 settimane di trattamento. I partecipanti del Sottostudio 3 e del Sottostudio A dovrebbero essere iscritti al Sottostudio 4.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

379

Fase

  • Fase 2
  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Prov. de Buenos Aires
      • Ciudadela, Prov. de Buenos Aires, Argentina, 1702
        • Instituto Medico Elsa Perez(I.M.E.P)
      • Ciudadela, Prov. de Buenos Aires, Argentina, B1702GIK
        • Instituto Medico Elsa Perez (I.M.E.P.) (Local Lab)
      • Ciudadela, Prov. de Buenos Aires, Argentina, B1702GIK
        • Instituto Medico Elsa Perez (I.M.E.P.) (Pharmacy)
      • Hurlingham, Prov. de Buenos Aires, Argentina, B1686NCI
        • Estudio de La Vision (OCT, Ophthalmoscopy)
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DEJ
        • Instituto Medico de la Fundacion Estudios Clinicos
      • Rosario, Santa Fe Province, Argentina, S2000AUC
        • Gastroenterologia Rosario (Endoscopy)
      • Rosario, Santa Fe Province, Argentina, S2000CTC
        • Microcirugia Ocular SA (OCT, Ophthalmoscopy)
      • Rosario, Santa Fe Province, Argentina, S2000KZD
        • Consultorios extemos de Sanatorio Parque (PFT with DLCO, Pulmonar Functional Test with DLCO)
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, T4000AXL
        • Centro de Investigaciones Médicas Tucuman
    • New South Wales
      • Macquarie University, New South Wales, Australia, 2109
        • Macquarie University Hospital
      • Macquarie University, New South Wales, Australia, 2109
        • Macquarie University Hospital Pharmacy
      • Macquarie University, New South Wales, Australia, 2109
        • Macquarie Respiratory Services
      • Macquarie University, New South Wales, Australia, 2109
        • Macquarie University Hospital Clinical Trials
      • Macquarie University, New South Wales, Australia, 2109
        • MQ Health Ophthalmology
    • Queensland
      • Brisbane, Queensland, Australia, 4029
        • Royal Brisbane & Women's Hospital
      • North Mackay, Queensland, Australia, 4740
        • Coral Sea Clinical Research Institute
    • Victoria
      • Bellfield, Victoria, Australia, 3081
        • MCES Practice Pty Ltd operating as Comprehensive Eye Surgeons
      • Epping, Victoria, Australia, 3076
        • The Northern Hospital
      • Heidelberg, Victoria, Australia, 3084
        • Austin Hospital
      • Melbourne, Victoria, Australia, 3011
        • Vision Eye Institute
      • Melbourne, Victoria, Australia, 3011
        • Footscray Hospital
      • Parkville, Victoria, Australia, 3050
        • The Royal Melbourne Hospital
      • Rosanna, Victoria, Australia, 3084
        • Heidelberg Eye Clinic
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • Fiona Stanley Hospital
      • Nedlands, Western Australia, Australia, 6009
        • Lions Eye Institute Limited
      • O'Connor, Western Australia, Australia, 6163
        • The trustee for The RTS Unit Trust trading as Respiratory Testing Services
      • Graz, Austria, 8036
        • LKH Universitats-Klinikum Graz
      • Innsbruck, Austria, A-6020
        • Medical University Innsbruck, Internal Medicine Ⅰ
      • Vienna, Austria, 1090
        • AKH Wien- Universitatsklinik fiir Innere Medizin III
      • Vienna, Austria, 1090
        • Univ.-Professor Dr. Mehrdad Baghestanian
      • Vienna, Austria, 1090
        • AKH Wien- Universitatsklinik fur Innere Medizin III
      • Ghent, Belgio, 9000
        • Universitair Ziekenhuis Gent
      • Ghent, Belgio, 9000
        • AZ Maria-Middelares
      • Leuven, Belgio, 3000
        • Universitaire Ziekenhuizen Leuven
      • Roeselare, Belgio, 8800
        • Campus Brugsesteenweg
      • Roeselare, Belgio, 8800
        • Campus Rumbeke
      • Torhout, Belgio, 8820
        • Campus Rembert Torhout
      • Yvoir, Belgio, 5530
        • Centre Hospitalier Universitaire UCL Namur - Site Godinne
      • Homyel, Bielorussia, 246029
        • Institution "Gomel Regional Clinical Hospital"
      • Minsk, Bielorussia, 220096
        • Health care Institution "10th City Clinical Hospital"
      • Mogilev, Bielorussia, 212018
        • Health Care Institution "Mogilev Hospital #1"
      • Vitebsk, Bielorussia, 210037
        • Health Care Institution "Vitebsk Regional Clinical Hospital"
      • Vitebsk, Bielorussia, 210604
        • Healthcare Institution "Vitebsk Regional Clinical Specialized Center"
      • Sofia, Bulgaria, 1527
        • UMHAT "Tsaritsa Yoanna-ISUL" EAD
      • Sofia, Bulgaria, 1431
        • "DCC Alexandrovska", EOOD
      • Sofia, Bulgaria, 1606
        • ,,University multiprofile hospital for active treatment and emergency medicine N.I. Pirogov" EAD
    • Quebec
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Electrocardiogram Clinic)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Endoscopy Clinic)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Pharmacy)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Radiology)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Research Site)
      • Montreal, Quebec, Canada, H4A 3J1
        • Centre for Innovative Medicine - Research Institute of the McGill University Health Centre(Pulmonary
      • Montreal, Quebec, Canada, H4P 2S4
        • Eye Health MD (Ophthalmology)
      • Horažďovice, Cechia, 341 01
        • MUDr. Jaroslava Skalova
      • Hradec Králové, Cechia, 500 12
        • Hepato-gastroenterologie HK, s.r.o.
      • Hradec Králové, Cechia, 500 12
        • VISUS, spol s.r.o.
      • Klatovy, Cechia, 339 01
        • GASTRO JeKa, s.r.o.
      • Klatovy, Cechia, 339 01
        • Klatovska nemocnice a.s.
      • Olomouc, Cechia, 779 00
        • PreventaMed s.r.o.
      • Olomouc, Cechia, 779 00
        • Ocni ordinace Olomouc
      • Olomouc, Cechia, 779 00
        • MUDr. Pavlina Kazinotova s.r.o.
    • RM
      • Santiago, RM, Chile, 8330034
        • Centro de Investigaciones Clinicas de la Universidad Catolica
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 7620157
        • Clinica Universidad de Los Andes
      • Santiago, Santiago Metropolitan, Chile, 8330336
        • CeCim Biocinetic
    • Quindío Department
      • Armenia, Quindío Department, Colombia, 630004
        • IPS Fundacion Cardiomet CEQUIN
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombia, 760035
        • Centro de lnvestigaciones Clinicas S.A.S
      • Daegu, Corea del Sud, 41404
        • Kyungpook National University Chilgok Hospital
      • Daegu, Corea del Sud, 41944
        • Kyungpook National University Hospital
      • Daegu, Corea del Sud, 41944
        • Endoscopy Facility in kyungpook National University Hospital
      • Daegu, Corea del Sud, 41944
        • OCT Facility In kyungpook National University Hospital
      • Daegu, Corea del Sud, 41944
        • PFT Facility in Kyungpook National University Hospital
      • Daejeon, Corea del Sud, 34943
        • The Catholic University of Korea, Daejeon ST. Mary's Hospital
      • Incheon, Corea del Sud, 21565
        • Gachon University Gil Medical Center
      • Seongnam-si, Corea del Sud, 13496
        • CHA University Bundang CHA Hospital
      • Seoul, Corea del Sud, 06273
        • Gangnam Severance Hospital, Yonsei University Health System
      • Seoul, Corea del Sud, 06973
        • Chung-Ang University Hospital
      • Seoul, Corea del Sud, 02447
        • Kyunghee University Medical Center
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Corea del Sud, 10326
        • Dongguk University Ilsan Hospital
      • Zagreb, Croazia, 10000
        • University Hospital Center Zagreb
      • Aalborg, Danimarca, 9000
        • Aalborg University Hospital, Department of Medical Gastroenterology, Medicinerhuset
      • Hvidovre, Danimarca, 2650
        • Hvidovre University Hospital
      • Alexandria, Egitto, 21131
        • Alexandria Clinical Research Center , Faculty of Medicine , Alexandria University
      • Cairo, Egitto
        • National Hepatology and Tropical Medicine Research Institute
      • Cairo, Egitto, 11556
        • Ain Shams University Hospital
      • Cairo, Egitto
        • Air Force Specialized Hospital(AFSH)
      • Cairo, Egitto
        • Cairo University , Kasr Al Aini Hospital
      • Dakahlia, Egitto
        • Egyptian Liver Research Institute and Hospital ( ELRIAH)
      • Giza, Egitto
        • Theodor Bilharz Research Institute Research Ethics Committee
      • Menofeya, Egitto, 32511
        • National Liver Institute
      • Amiens, Francia, 80054
        • CHU Amiens Picardie
      • Clermont-Ferrand, Francia, 63000
        • Chu Gabriel Montpied
      • Clermont-Ferrand, Francia, 63000
        • CHU De Clermont Ferrand - Hopital Estaing
      • Grenoble, Francia, 38043
        • CHU Grenoble Alpes - Hopital Michallon
      • Grenoble, Francia, 38043
        • Endoscopy: CHU Grenoble Alpes- Hopital Michallon
      • La Roche-sur-Yon, Francia, 85925
        • CHD Vendee, Unite de Recherche Clinique
      • Lille, Francia, 59037
        • CHU de Lille - Hôpital Claude Huriez
      • Lille, Francia, 59037
        • Optical Coherence Tomography and Ophthalmology CHU de Lille Hopital Roger Salengro
      • Lille, Francia, 59037
        • Pulmonary Function Test CHU Lille, Institut Coeur Poumon
      • Montpellier, Francia, 34295
        • CHU Saint-Eloi
      • Montpellier, Francia, 34295
        • Hopital Saint-Eloi - Pole Digestif - Hgea Recherche Clinique - Rdc
      • Nice, Francia, 06202
        • CHU de Nice, Hopital 1'Archet 2
      • Reims, Francia, 51100
        • Hopital Maison Blanche, CHU DE REIMS
      • Reims, Francia, 51092
        • Hopital Robert Debre
      • Reims, Francia, 51100
        • Hopital Robert Debre CHU DE REIMS
      • Saint-Etienne, Francia, 42055
        • CHU Saint Etienne - Hôpital Nord
      • Saint-Priest-en-Jarez, Francia, 42270
        • Optical Coherence Tomography and Ophthalmology
      • Saint-Priest-en-Jarez, Francia, 42270
        • Pulmonary Function Test
      • Toulouse, Francia, 31059
        • Hopital Rangueil
      • Toulouse, Francia, 31300
        • Hopital Purpan PPR pole cephalique
      • Vandœuvre-lès-Nancy, Francia, 54511
        • CHRU Nancy Brabois
      • Tbilisi, Georgia, 0160
        • LTD Aversi Clinic
      • Tbilisi, Georgia, 0159
        • LTD Institute of Clinical Cardiology
      • Tbilisi, Georgia, 0160
        • JSC Infectious Diseases, AIDS and Clinical Immunology Research Center
      • Tbilisi, Georgia, 0160
        • LTD Academician Nikoloz Kipshidze Central University Clinic
      • Tbilisi, Georgia, 0172
        • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center, LTD
      • Tbilisi, Georgia, 0179
        • LTD Medical Center "CITO"
      • Augsburg, Germania, 86156
        • Universitaetsklinikum Augsburg
      • Brandenburg an der Havel, Germania, 14770
        • Staedtisches Klinikum Brandenburg
      • Frankfurt, Germania, 60431
        • Prof. Dr. med. Dr. med. Habil. Jens Buhren, FEBO
      • Frankfurt am Main, Germania, 60431
        • Agaplesion Markus Krankenhaus
      • Hamburg, Germania, 20251
        • HaFCED e.K. - Hamburgisches Forschungsinstitut für chronisch entzündliche Darmerkrankungen
      • Jena, Germania, 07747
        • Universitaetsklinikum Jena
      • Jena, Germania, 07747
        • OCT/Ophtalmoscopy address: Universitaetsklinikum Jena
      • Jena, Germania, 07747
        • PFT address: Universitaetsklinikum Jena
      • Kassel, Germania, 34121
        • PFT address: Praxis fur Pneumologie und Allergologie
      • Kassel, Germania, 34177
        • OCT/Ophtalmoscopy address: Augenarztpraxis Dr. Karola Hassan
      • Kiel, Germania, 24105
        • Nordblick Augenklinik
      • Kiel, Germania, 24105
        • Universitatsklinikum Schleswig-Holstein- Campus Kiel
      • Nürtingen, Germania, 72622
        • Dr. Irina Hasewinkel
      • Nürtingen, Germania, 72622
        • Medius Klinik Nuertingen
    • Hassen
      • Kassel, Hassen, Germania, 34117
        • Gastroenterologie Opernstraβe
    • Chiba
      • Kashiwa-shi, Chiba, Giappone, 277-0871
        • Kokikai Tsujinaka Hospital Kashiwanoha
      • Nagareyama-shi, Chiba, Giappone, 270-0116
        • Ishii Eye Clinic
    • Fukuoka
      • Kitakyushu-shi, Fukuoka, Giappone, 807-8555
        • Hospital of the University of Occupational and Environmental Health
      • Kitakyusyu-shi, Fukuoka, Giappone, 802-8561
        • Kitakyushu Municipal Medical Center
    • Ibaraki
      • Toride-shi, Ibaraki, Giappone, 302-0014
        • Matsumoto Eye Clinic
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Giappone, 892-0846
        • Sameshima Hospital
      • Kagoshima, Kagoshima-ken, Giappone, 892-0824
        • Jiaikai Idzuro Imamura Hospital
      • Kagoshima, Kagoshima-ken, Giappone, 890-0062
        • Kagoshima Kouseiren Hospital
      • Kagoshima, Kagoshima-ken, Giappone, 892-0825
        • Sameshima Eye Clinic
    • Kumamoto
      • Kumamoto, Kumamoto, Giappone, 861-8520
        • Japanese Red Cross Kumamoto Hospital
    • Saga-ken
      • Saga, Saga-ken, Giappone, 849-8501
        • Saga University Hospital
    • Tokyo
      • Shinjuku-ku, Tokyo, Giappone, 169-0073
        • Japan Community Health Care Organization Tokyo Yamate Medical Center
      • Alexandroupoli, Grecia, 681 00
        • University General Hospital of Alexandroupoli
      • Athens, Grecia, 10676
        • General Hospital of Athens "Evangelismos"
    • Crete
      • Heraklion, Crete, Grecia, 71500
        • Univerisity General Hospital of Heraklion
      • Kochi, India, 682027
        • Aster Medcity, Aster DM Healthcare Ltd.
    • Gujarat
      • Surat, Gujarat, India, 395002
        • Surat Institute of Digestive Sciences
    • Haryana
      • Gurugram, Haryana, India, 122002
        • Fortis Memorial Research Institute
    • Maharashtra
      • Nagpur, Maharashtra, India, 440010
        • Midas Multispeciality Hospital Pvt. Ltd
    • Rajasthan
      • Jaipur, Rajasthan, India, 302001
        • S. R. Kalla Memorial Gastro & General Hospital
      • Afula, Israele, 1834111
        • Haemek Medical Center
      • Jerusalem, Israele, 9103102
        • Shaare Zedek Medical Center
      • Ramat Gan, Israele, 5262000
        • Chaim Sheba Medical Center
      • Tel Aviv, Israele, 6423906
        • Tel Aviv Sourasky Medical Center
      • Catania, Italia, 829-95126
        • Azienda Ospedaliera Ospedale Cannizzaro
      • Catanzaro, Italia, 88100
        • A.O. Mater Domini, U.O. Fisiopatologia Apparato Digerente Campus Universitario "Salvatore Venuta"
      • Catanzaro, Italia, 88100
        • A.O. Mater Domini, U.O. Fisiopatologia Apparato Digerente
      • Catanzaro, Italia, 88100
        • CAMPUS GERMANETO Magazzino farmaci e dispositivi medici, uffici
      • Pavia, Italia, 27100
        • Fondazione IRCCS Policlinico San Matteo - Centro per lo Studio e la Cura delle Amiloidosi Sistemiche
      • Rome, Italia, 00189
        • PFT address: Azienda Ospedaliero-Universitaria Sant' Andrea UOC Pneumologia
      • Verona, Italia, 37024
        • IRCCS Ospedale Sacro Cuore Don Calabria
      • Verona, Italia, 37134
        • OCT/PFT/Endoscopy address: CRC - Cenro Ricerche Cliniche di Verona
    • Foggia
      • San Giovanni Rotondo, Foggia, Italia, 71013
        • IRCCS Ospedale Casa Sollievo della Sofferenza
      • San Giovanni Rotondo, Foggia, Italia, 71013
        • OCT/ PFT/ Endoscopy address: IRCCS Ospedale Casa Sollievo della Sofferenza
    • MI
      • Milan, MI, Italia, 20132
        • Ospedale San Raffaele
    • Milan
      • Garbagnate Milanese, Milan, Italia, 20024
        • ASST Rhodense - Pneumology Unit
      • Milan, Milan, Italia, 20017 Rho
        • ASST Rhodense, U.O.C. Gastroenterologia ed Endoscopia Digestiva
      • Rho, Milan, Italia, 20017
        • ASST Rhodense - Ophthalmology Unit
    • Milano
      • Rozzano, Milano, Italia, 20089
        • Irccs Humanitas Research Hospital
    • Verona
      • Negrar, Verona, Italia, 37024
        • OCT/ PFT/ Endoscopy address: IRCCS Ospedale Sacro Cuore Don Calabria
      • Beirut, Libano, 166830
        • Hotel Dieu de France Hospital
      • Beirut, Libano, 1100 2807
        • Saint George University Hospital Medical Center
      • Beirut, Libano, 113-6044
        • Rafik Hariri University Hospital
      • Saida, Libano
        • Hammoud Hospital University Medical Center
      • Tripoli, Libano
        • Nini Hospital s.a:l
      • Vilnius, Lituania, LT-08661
        • Vilnius University Hospital Santaros Klinikos
      • Kuala Lumpur, Malaysia, 59100
        • University Malaya Medical Centre
      • Chihuahua City, Messico, 31203
        • Scientia Investigacion Clinica S.C.
      • Chihuahua City, Messico, 31020
        • Sanatorio Palmore A.C.
      • Chihuahua City, Messico, 31203
        • Vista Lasser de Chihuahua S.C.
      • Chihuahua City, Messico, 31283
        • Servicios Hospitalarios de México, S.A. de C.V.
      • Veracruz, Messico, 91900
        • FAICIC S. de R.L. de C.V.
      • Veracruz, Messico, 91910
        • Gabinete de Diagnostico COVADONGA
      • Veracruz, Messico, 91918
        • Alberto Collado Solorzano (Clinica Vision)
    • Jalisco
      • Guadalajara, Jalisco, Messico, 44130
        • Centro de Investigacion Medico Biologica Y Terapia Avanzada S.C.
      • Guadalajara, Jalisco, Messico, 44600
        • Global Glaucoma Institute
      • Guadalajara, Jalisco, Messico, 44600
        • Video Endoscopia Americas
      • Guadalajara, Jalisco, Messico, 44670
        • Comercializadora Winco S.A. de C.V.
    • Veracruz
      • Boca del Rio, Veracruz, Messico, 94299
        • Cirugia y Gastro de Veracruz S.A. de C.V. (Progastro)
      • Chisinau, Moldavia, 2005
        • "Sf. Arhanghel Mihail" Municipal Clinical Hospital, Department of Gastroenterology
      • Chisinau, Moldavia, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Department of Colorectal Surgery
      • Chisinau, Moldavia, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Department of Gastroenterology
      • Chisinau, Moldavia, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Outpatient Department
      • Amsterdam, Olanda, 1105 AZ
        • Academic Medical Centre
      • Utrecht, Olanda, 3584 CX
        • UMC Utrecht
      • Bystra, Polonia, 43-360
        • Centrum Pulmonologii i Torakochirurgii w Bystrej (DLCO)
      • Karkow, Polonia, 31-156
        • Specjalistyczne Gabinety Lekarskie LANDA
      • Krakow, Polonia, 30-033
        • Centre De La Vision Centrum Okulistyczne(OCT, Ophthalmoscopy)
      • Krakow, Polonia, 30-307
        • Medicina (Endoscopy)
      • Krakow, Polonia, 31-153
        • Centrum Medyczne EVITA(Endoscopy)
      • Lodz, Polonia, 90-752
        • IP Clinic Sp. z o.o.
      • Lodz, Polonia, 90-338
        • Centrum Medyczne "Ksiezy Mlyn" (OCT, Ophtalmoscopy)
      • Lodz, Polonia, 93-513
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatolog i im. M. Kopernika w Lodzi
      • Lodz, Polonia, 90-338
        • (Centrum Medyczne Ksiezy Mlyn (OCT and Ophthalmoscopy)
      • Lodz, Polonia, 90-644
        • AMICARE Sp. z o.o. sp.k
      • Lodz, Polonia, 91-053
        • Centra Medyczne Medyceusz (DLCO)
      • Lodz, Polonia, 92-551
        • Salve Health Care Sp. o.o., (PFT and Endoscopy)
      • Nowy Targ, Polonia, 34-400
        • Allmedica Badania Kliniczne Sp. z o.o. Sp. k.
      • Oświęcim, Polonia, 32-600
        • Medicome Sp. Z O.O
      • Piotrkow Trybunalski, Polonia, 97-300
        • Przychodnia Okulistyczna "Oculus" Barbara Cybulska (OCT, Ophtalmoscopy)
      • Piotrkow Trybunalski, Polonia, 97-300
        • Samodzielny Szpital Wojewodzki im. Mikolaja Kopernika (Endoscopy)
      • Piotrokow Trybunalski, Polonia, 97-300
        • Trialmed CRS
      • Poznan, Polonia, 60-529
        • Solurmed Centrum Medyczne
      • Poznan, Polonia, 60-538
        • OCU Service Mikolaj Meller Sp.j.(OCT, Ophtalmoscopy)
      • Rzeszów, Polonia, 35-326
        • Centrum Medyczne Medyk
      • Rzeszów, Polonia, 35-055
        • Kliniczny Szpital Wojewodzki Nr 1 im. Fryderyka Chopina w Rzeszowie (Ophthalmpscopy)
      • Rzeszów, Polonia, 35-241
        • Podkarpackie Centrum Chorob Plue w Rzeszowie (DLCO)
      • Strzegom, Polonia, 58-150
        • Strzegomskie Centrum Medyczno - Diagnostyczne Sp. z o.o. (Endoscopy)
      • Swidnica, Polonia, 58-100
        • DC-MED
      • Swidnica, Polonia, 58-100
        • Centrum Medyczne EZ-MEDICA (OCT, Ophtalmoscopy)
      • Swidnica, Polonia, 58-100
        • Szpital "Latawiec" -Poradnia Gruzlicy i Chorob Pluc (PFT)
      • Warsaw, Polonia, 00-635
        • Centrum Zdrowia MDM
      • Warsaw, Polonia, 00-631
        • Centrum Zdrowia MDM (OCT,opthalmoscopy)
      • Warsaw, Polonia, 01-138
        • Instytut Gruzlicy i Chorob Pluc(DLCO)
      • Warsaw, Polonia, 02-653
        • Endoterapia PFG (Endoscopy)
      • Warsaw, Polonia, 02-653
        • Instytut Oka (OCT, Ophtalmoscopy)
      • Warsaw, Polonia, 03-712
        • Specjalistyczne Gabinety Lekarskie Body Clinic
      • Warsaw, Polonia, 03-731
        • Centrum Okulistyczne JASKRA (OCT, Ophthalmoscopy)
      • Warsaw, Polonia, 04-141
        • Wojskowy lnstytut Medyczny (PFT)
      • Wroclaw, Polonia, 60-681
        • EuroMediCare Szpital Specjalistyczny z Przychodniit (Endoscopy)
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polonia, 60-681
        • NSZOZ Termedica
      • Liverpool, Regno Unito, L7 8XP
        • Royal Liverpool University Hospital
      • London, Regno Unito, SE1 9RT
        • Guys & St Thomas Hospital
      • Norwich, Regno Unito, NR4 7UQ
        • Quadram Institute Clinical Research Facility
      • Bucharest, Romania, 012015
        • SC Centrul Medical Medicum SRL, Specialitatea Gastroenterologie
      • Bucharest, Romania, 022328
        • Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie
    • JUD. CLUJ
      • Cluj-Napoca, JUD. CLUJ, Romania, 400006
        • Spitalul Clinic Judetean de Urgenta Cluj Napoca
    • Jud.constanta
      • Constanța, Jud.constanta, Romania, 900591
        • Centrul de Diagnostic si Tratament Affidea, Specialitatea Medicina Interna
      • Kemerovo, Russia, 650066
        • SAIH "Kemerovo Regional Clinical Hospital"
      • Novosibirsk, Russia, 630005
        • LLC "SibNovoMed"
      • Novosibirsk, Russia, 630007
        • Gastrocenter
      • Novosibirsk, Russia, 630007
        • LLC "Novosibirskiy Gastrocentr''
      • Novosibirsk, Russia, 630084
        • Hospital #12
      • Novosibirsk, Russia, 630091
        • LLC "Siberian Center for Prevention and Treatment of Myopia Eye"
      • Novosibirsk, Russia, 630099
        • Joint Stock Company Medical Center "AVICENNA"
      • Omsk, Russia, 644013
        • BHI of Omsk region "Clinical Oncology Dispensary"
      • Omsk, Russia, 644024
        • Clinicodiagnostic Center "Ultramed"
      • Omsk, Russia, 644070
        • Medical center "Intervzglyad"
      • Saint Petersburg, Russia, 191015
        • FSBI of Higher Education " North-Western Medical University n.a.I.I. Mechnikov '' of MoH RF
      • Saint Petersburg, Russia, 195067
        • FSBI of Higher Education "North-Western Medical University n.a.I.I. Mechnikov'' of MoH RF
      • Stavropol, Russia, 355017
        • Autonomous Noncommercial Medical Organization "Stavropol Regional Clinical
    • Stavropol Kray
      • Pyatigorsk, Stavropol Kray, Russia, 357502
        • LLC "Polyclinic of ultrasonography 4D"
      • Belgrade, Serbia, 11000
        • Clinical Center Zvezdara
      • Banská Bystrica, Slovacchia, 975 17
        • Fakultna nemocnica s poliklinikou F.D.Roosevelta
      • Bardejov, Slovacchia, 08501
        • ALIAN. s.r.o .. Ambulancia vnutorneho lekarstva
      • Košice, Slovacchia, 040 13
        • ENDOMED, s.r.o. Gastroenterologicka ambulancia
      • Lipany, Slovacchia, 082 71
        • Opthalmology outpatient clinic, MUDr. Michal Popovec, s.r.o.
      • Nitra, Slovacchia, 949 01
        • KM Management spol.s.r.o. Gastroenterologicke a hepatologicke centrum
      • Prešov, Slovacchia, 080 01
        • GASTRO LM s.r.o., Gastroenterologicka ambulancia
      • Prešov, Slovacchia, 080 01
        • Pneumology: PULMO, s.r.o.
      • Las Palmas de Gran Canaria, Spagna, 35010
        • Hospital Universitario de Gran Canaria Dr. Negrín
      • Madrid, Spagna, 28046
        • Hospital Universitario La Paz
    • Ciudad REAL
      • Tomellso, Ciudad REAL, Spagna, 13700
        • Hospital General de Tomelloso
    • Alabama
      • Dothan, Alabama, Stati Uniti, 36301
        • Digestive Health Specialists
      • Dothan, Alabama, Stati Uniti, 36301
        • Dothan Eyecare-Dr. Brent McKinley (OCT Location)
      • Dothan, Alabama, Stati Uniti, 36301
        • Center for Digestive Health (Endoscopy Location)
      • Dothan, Alabama, Stati Uniti, 36301
        • Pulmonary Associates (PFT Location)
      • Dothan, Alabama, Stati Uniti, 36305
        • Flowers Hospital (Imaging Location)
      • Mobile, Alabama, Stati Uniti, 36608
        • Digestive Health Specialists (Satellite Clinic Location)
      • Mobile, Alabama, Stati Uniti, 36608
        • Premier Medical Group East (Opthalmology & Optometry Facility)
      • Mobile, Alabama, Stati Uniti, 36608
        • Pulmonary Associates (Chest X-Ray & PFT Facility)
      • Mobile, Alabama, Stati Uniti, 36608
        • Surgicare of Mobile (Endoscopy & Biopsy Facility)
    • Arizona
      • Peoria, Arizona, Stati Uniti, 85381
        • Arizona Retina Institute/ Phoenix Retina Associates(OCT)
      • Peoria, Arizona, Stati Uniti, 85381
        • SimonMed Imaging (Imaging)
      • Sun City, Arizona, Stati Uniti, 85351
        • Sun City Endoscopy Center (Endoscopy)
    • California
      • Apple Valley, California, Stati Uniti, 92307
        • Om Research LLC
      • Apple Valley, California, Stati Uniti, 92307
        • Victor Valley Advanced Imaging
      • La Jolla, California, Stati Uniti, 92037
        • UCSD lnvestigational Drug Service Pharmacy
      • La Jolla, California, Stati Uniti, 92093
        • Shiley Eye Institute (OCT)
      • La Jolla, California, Stati Uniti, 92037
        • Koman Family Outpatient Pavilion (ENDO)
      • La Jolla, California, Stati Uniti, 92037
        • Perlman Medical Offices
      • La Jolla, California, Stati Uniti, 92037
        • UCSD Clinical and Translational Research Institute
      • La Jolla, California, Stati Uniti, 92037
        • UCSD Health System (Endo/PFT/DLCO)
      • Lancaster, California, Stati Uniti, 93534
        • Om Research LLC
      • Lancaster, California, Stati Uniti, 93534
        • A V Pediatrics, Allergy and Family Medicine - PFT
      • Lancaster, California, Stati Uniti, 93534
        • Advanced Endoscopy and Pain Center - Colonoscopy
      • Lancaster, California, Stati Uniti, 93534
        • Advanced Imaging Center - Chest X-Ray
      • Lancaster, California, Stati Uniti, 93534
        • Antelope Valley Eye Care - Ophthalmologist
      • Lancaster, California, Stati Uniti, 93534
        • AV Pediatrics Allergy and Family Medicine
      • Lancaster, California, Stati Uniti, 93534
        • Jatinder S. Pruthi, MD FACG CPI
      • Murrieta, California, Stati Uniti, 92563
        • United Medical Doctors
      • Victorville, California, Stati Uniti, 92392
        • Retina Consultants of Southern California
      • Victorville, California, Stati Uniti, 92395
        • Physicians Surgery Center
    • Colorado
      • Colorado Springs, Colorado, Stati Uniti, 80907
        • Peak Gastroenterology Associates
      • Colorado Springs, Colorado, Stati Uniti, 80903
        • Front Range Endoscopy Center
      • Colorado Springs, Colorado, Stati Uniti, 80909
        • Colorado Springs Pulmonary Consultants, PC
      • Colorado Springs, Colorado, Stati Uniti, 80909
        • The Wright Eye Center (OCT Facility)
      • Colorado Springs, Colorado, Stati Uniti, 80919
        • Colorado Springs Imaging (Ultrasound and MRE Location)
    • Florida
      • Boca Raton, Florida, Stati Uniti, 33487
        • Xera Med Research
      • Boynton Beach, Florida, Stati Uniti, 33472
        • RecioMed Clinical Research Network, Inc
      • Brandon, Florida, Stati Uniti, 33511
        • Florida Advanced Gastroenterology Center - Rahman Nakshabendi MD and Imad Nakshabendi, MD
      • Clearwater, Florida, Stati Uniti, 33756
        • West Coast Endoscopy Center (Endoscopy Procedures)
      • Clearwater, Florida, Stati Uniti, 33756
        • Bay Area Chest Physicians, P.A. (Pulmonary Function Test)
      • Clearwater, Florida, Stati Uniti, 33761
        • Northwood Vision (Optical Coherence Tomography)
      • Clearwater, Florida, Stati Uniti, 33761
        • Safety Harbor Surgery (Endoscopy Procedures)
      • Clearwater, Florida, Stati Uniti, 33762
        • Gastro Florida (Regulatory Administrative Duties)
      • Coral Gables, Florida, Stati Uniti, 33134
        • Beraja Medical Institute (OCT)
      • Hialeah, Florida, Stati Uniti, 33012
        • Advanced Eye Center
      • Jacksonville, Florida, Stati Uniti, 32256
        • Encore Borland-Groover Clinical Research
      • Jacksonville, Florida, Stati Uniti, 32207
        • UF Health Imaging Center-Emerson (chest x-rays)
      • Jacksonville, Florida, Stati Uniti, 32207
        • UF Health Laboratory Emerson (blood draws)
      • Jacksonville, Florida, Stati Uniti, 32209
        • UF Health Jacksonville Respiratory Therapy (PFT and DLCO)
      • Jacksonville, Florida, Stati Uniti, 32209
        • UF Health Jacksonville-Faculty Clinic (ileocolonoscopy and biopsy)
      • Jacksonville, Florida, Stati Uniti, 32209
        • UF Health Opthalmology - Jacksonville (Ophthalmology with OCT)
      • Jacksonville, Florida, Stati Uniti, 32209
        • UF Health Radiology-Jacksonville (chest x-rays)
      • Jacksonville, Florida, Stati Uniti, 32216
        • Cisca Pulmonary & Critical Care (PFT Facility)
      • Jacksonville, Florida, Stati Uniti, 32216
        • Nicolitz Eye Consultants (OCT Facility)
      • Jacksonville, Florida, Stati Uniti, 32256
        • Borland-Groover Clinic (Endoscopy Facility)
      • Jupiter, Florida, Stati Uniti, 33458
        • Jupiter Outpatient Surgery Center
      • Kissimmee, Florida, Stati Uniti, 34741
        • IHS Health, LLC
      • Largo, Florida, Stati Uniti, 33773
        • Lee Shettle Eye & Hearing (Ophthalmoscopy Only)
      • Miami, Florida, Stati Uniti, 33133
        • Infinite Clinical Research
      • Miami, Florida, Stati Uniti, 33156
        • Research Associates of South Florida
      • Miami, Florida, Stati Uniti, 33176
        • Anchor Medical Research, LLC
      • Miami, Florida, Stati Uniti, 33134
        • The Endoscopy Center (Endoscopy Procedure)
      • Miami, Florida, Stati Uniti, 33173
        • Juan Barrio, MD (PFT when needed)
      • Miami, Florida, Stati Uniti, 33133
        • Pulmonology Physicians of South Florida
      • Miami, Florida, Stati Uniti, 33133
        • Reina Eye Care P.A.
      • Miami, Florida, Stati Uniti, 33155
        • La Salud Research Clinic Inc.
      • Miami, Florida, Stati Uniti, 33156
        • South Florida Center for Endoscopy and Digestive Disease, LLC
      • Naples, Florida, Stati Uniti, 34102
        • Gastroenterology Group of Naples
      • Naples, Florida, Stati Uniti, 34102
        • Gulfshore Endoscopy Center
      • Naples, Florida, Stati Uniti, 34103
        • Retina Consultants of Southwest Florida OCT only
      • Naples, Florida, Stati Uniti, 34109
        • Lisette Delgado Sanchez, MD PFT only
      • Orlando, Florida, Stati Uniti, 32825
        • Pediatric & Adult Research Center
      • Palmetto Bay, Florida, Stati Uniti, 33157
        • IMIC Inc.
      • Palmetto Bay, Florida, Stati Uniti, 33157
        • IMIC Inc
      • Port Orange, Florida, Stati Uniti, 32127
        • Advanced Medical Research Center
      • Seminole, Florida, Stati Uniti, 33777
        • Bardmoor GastroEnterology
      • South Miami, Florida, Stati Uniti, 33143
        • Larkin Community Hospital (Endoscopy Procedure)
      • St. Petersburg, Florida, Stati Uniti, 33705
        • St. Petersburg Endoscopy Center (Endoscopy Procedures)
      • St. Petersburg, Florida, Stati Uniti, 33707
        • Pasadena Center for Asthma and Lung Disorders (PFT and DLCO Only)
      • St. Petersburg, Florida, Stati Uniti, 33709
        • Bay Area Endoscopy and Surgery Center (Endoscopy only)
      • St. Petersburg, Florida, Stati Uniti, 33709
        • Theia Clinical Research, LLC
      • St. Petersburg, Florida, Stati Uniti, 33710
        • Advanced Research Institute Inc.(IP and PFT)
      • Sun City Center, Florida, Stati Uniti, 33573
        • Absolute Surgical Specialist - Craig Amshel, MD
      • Tampa, Florida, Stati Uniti, 33612
        • USF Health Morsani Center for Advanced Healthcare
      • Tampa, Florida, Stati Uniti, 33606
        • USF Health South Tampa Center for Advanced Healthcare
      • Tampa, Florida, Stati Uniti, 33609
        • GCP Clinical Research,LLC
      • Tampa, Florida, Stati Uniti, 33609
        • South Tampa Surgery Center
      • Tampa, Florida, Stati Uniti, 33609
        • Newsome Eye Specialist (OCT Procedures Only)
      • Tampa, Florida, Stati Uniti, 33606
        • Lab - Processing/ Storage
      • Tampa, Florida, Stati Uniti, 33609
        • LoCicero Medical Group
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30342
        • Atlanta Gastroenterology Associates
      • Atlanta, Georgia, Stati Uniti, 30309
        • Digestive Healthcare of Georgia
      • Atlanta, Georgia, Stati Uniti, 30324
        • Ross Eyecare - Opthalmoscopy and OCT
      • Atlanta, Georgia, Stati Uniti, 30342
        • Atlanta Gastroenterology Associates (endoscopy only)
      • Atlanta, Georgia, Stati Uniti, 30342
        • Atlanta Gastroenterology Associates(IP only)
      • Atlanta, Georgia, Stati Uniti, 30309
        • Peachtree Allergy and Asthma Clinic - Chest X-rays and PFTs
    • Illinois
      • Arlington Heights, Illinois, Stati Uniti, 60005
        • GI Alliance
      • Arlington Heights, Illinois, Stati Uniti, 60005
        • Northwest Endoscopy Center (Endoscopy)
      • Gurnee, Illinois, Stati Uniti, 60031
        • GI Alliance (PFT)
      • Gurnee, Illinois, Stati Uniti, 60031
        • Illinois Gastroenterology Group-Gurnee (Patients Seen; IP Delivered)
      • Gurnee, Illinois, Stati Uniti, 60031
        • Medical Eye Services LTD (Ophthalmoscopy with OCT)
      • Lake Bluff, Illinois, Stati Uniti, 60044
        • North Shore Endoscopy Center (Endoscopy)
      • Libertyville, Illinois, Stati Uniti, 60048
        • Libertyville Imaging Center (Diagnostic Imaging)
      • Morton Grove, Illinois, Stati Uniti, 60053
        • 3T Imaging of Morton Grove (Diagnostic Imaging)
    • Maryland
      • Columbia, Maryland, Stati Uniti, 21045
        • Cascades Endoscopy Center
      • Columbia, Maryland, Stati Uniti, 21044
        • Charter Radiology
      • Columbia, Maryland, Stati Uniti, 21045
        • Gastro Center of Maryland, LLC
      • Hanover, Maryland, Stati Uniti, 21076
        • Kaylani Eye Care ( Optical Coherence Tomography and Opthalmoscopy only)
      • Laurel, Maryland, Stati Uniti, 20707
        • Lung Center (Pulmonary Function Test only)
    • Mississippi
      • Jackson, Mississippi, Stati Uniti, 39216
        • Southern Therapy and Advanced Research, LLC
      • Jackson, Mississippi, Stati Uniti, 39216
        • A Terrell Williams, MD, PLLC (OCT)
      • Jackson, Mississippi, Stati Uniti, 39216
        • Jackson Pulmonary Associates (PFT)
      • Jackson, Mississippi, Stati Uniti, 39216
        • St. Dominic Ambulatory Surgery Center (colonoscopy, Endoscopy)
    • Missouri
      • Creve Coeur, Missouri, Stati Uniti, 63141
        • Barnes-Jewish West County Hospital (Additional Endoscopy Location)
      • St Louis, Missouri, Stati Uniti, 63110
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Stati Uniti, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Stati Uniti, 63108
        • Washington University School of Medicine
    • New Jersey
      • Freehold, New Jersey, Stati Uniti, 07728
        • Allied Health Clinical Research Organization, LLC
      • Freehold, New Jersey, Stati Uniti, 07728
        • Freehold Endoscopy Associates, LLC d/b/a Endoscopy Center of Monmouth County
      • Freehold, New Jersey, Stati Uniti, 07728
        • Freehold Ophthalmology
      • Freehold, New Jersey, Stati Uniti, 07728
        • Monmouth Ocean Pulmonary Medicine
      • Freehold, New Jersey, Stati Uniti, 07728
        • Princeton Radiology
    • New York
      • New York, New York, Stati Uniti, 10016
        • NYU Langone Health
      • New York, New York, Stati Uniti, 10016
        • NYU Langone Inflammatory Bowel Disease Center
      • New York, New York, Stati Uniti, 10016
        • NYU Langone Eye Center (Ophthalmology)
      • New York, New York, Stati Uniti, 10016
        • NYU Langone Health - Ambulatory Care Center
      • New York, New York, Stati Uniti, 10016
        • NYU Langone Health, Investigational Pharmacy, Perlmutter Cancer Center
      • New York, New York, Stati Uniti, 10016
        • NYU Pulmonary and Critical Care Associates (Pulmonary)
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28215
        • Carolinas Research Center
      • Charlotte, North Carolina, Stati Uniti, 28204
        • Queen City Gastroenterology and Hepatology (Endoscopy)
      • Charlotte, North Carolina, Stati Uniti, 28211
        • Greenman Eye Associates (OCT)
      • Charlotte, North Carolina, Stati Uniti, 28273
        • Cornerstone Medical (Imaging & PFT)
    • Ohio
      • Chardon, Ohio, Stati Uniti, 44024
        • Geauga Sleep Center(PFT only)
      • Cincinnati, Ohio, Stati Uniti, 45219
        • UC Health Physicians Office
      • Cincinnati, Ohio, Stati Uniti, 45229
        • UC Health (Pulmonary Function Testing)
      • Cincinnati, Ohio, Stati Uniti, 45219
        • UC Health Hoxworth (OCT only)
      • Cincinnati, Ohio, Stati Uniti, 45219
        • University of Cincinnati Medical Center (PFT and Endoscopy location)
      • Mentor, Ohio, Stati Uniti, 44060
        • Great Lakes Gastroenterology Research, LLC
      • Mentor, Ohio, Stati Uniti, 44060
        • The Endoscopy Center of Lake County
      • Mentor, Ohio, Stati Uniti, 44060
        • Ophthalmic Physicians Incorporated (OCT Only)
      • Mentor, Ohio, Stati Uniti, 44060
        • Vitreo Retinal Consultants(OCT only)
      • Willoughby, Ohio, Stati Uniti, 44094
        • Lake Pulmonary Associates (PFT only)
      • Willoughby Hills, Ohio, Stati Uniti, 44094
        • Retina Specialists of Ohio(OCT only)
    • Oklahoma
      • Norman, Oklahoma, Stati Uniti, 73071
        • Norman Endoscopy Center
      • Norman, Oklahoma, Stati Uniti, 73071
        • Physicians and Surgeons X-Ray
      • Oklahoma City, Oklahoma, Stati Uniti, 73118
        • Central Sooner Research
      • Oklahoma City, Oklahoma, Stati Uniti, 73102
        • Hightower Clinical
      • Oklahoma City, Oklahoma, Stati Uniti, 73102
        • Saint Anthony Endoscopy Center
      • Oklahoma City, Oklahoma, Stati Uniti, 73102
        • SSM Health, Saint Anthony Hospital
      • Oklahoma City, Oklahoma, Stati Uniti, 73120
        • Johnston Opthalmology
    • Pennsylvania
      • Hershey, Pennsylvania, Stati Uniti, 17033
        • Penn State Milton S. Hershey Medical Center
    • Texas
      • Austin, Texas, Stati Uniti, 78705
        • Central Texas Clinical Research
      • Cypress, Texas, Stati Uniti, 77429
        • Houston Pulmonary Sleep and Allergy Associates (PFT)
      • Houston, Texas, Stati Uniti, 77030
        • The University of Texas Health Science Center at Houston
      • Houston, Texas, Stati Uniti, 77030
        • Baylor St. Luke's Medical Center
      • Houston, Texas, Stati Uniti, 77047
        • Pearland Surgery Center
      • Houston, Texas, Stati Uniti, 77030
        • Alkek Eye Center Jamail Specialty Care Center (OCT)
      • Houston, Texas, Stati Uniti, 77024
        • Houston Eye Associates (For Eye Examination)
      • Houston, Texas, Stati Uniti, 77030
        • Baylor College of Medicine - Baylor St. Luke's Medical Center
      • Houston, Texas, Stati Uniti, 77030
        • Baylor St. Luke's Medical Center - McNair Campus (pharmacy)
      • Houston, Texas, Stati Uniti, 77030
        • Baylor St. Luke's Medical Center - McNair Campus
      • Houston, Texas, Stati Uniti, 77030
        • Baylor St. Luke's Medical Center Endoscopy - McNair Campus
      • Houston, Texas, Stati Uniti, 77030
        • Mann Eye Institute
      • Houston, Texas, Stati Uniti, 77030
        • Memorial Hermann Hospital- TMC Investigational Drugs Services Pharmacy (Drug Storage)
      • Houston, Texas, Stati Uniti, 77034
        • Bay Area Endoscopy Center, LLC
      • Houston, Texas, Stati Uniti, 77055
        • Memorial Endoscopy Center (For Colonoscopy)
      • Houston, Texas, Stati Uniti, 77065
        • Eye Specialists of Texas
      • Houston, Texas, Stati Uniti, 77065
        • Northside Gastroenterology Associates PA
      • Houston, Texas, Stati Uniti, 77079
        • Memorial Pulmonology(For PFT)
      • Houston, Texas, Stati Uniti, 77204
        • Digestive Health Associates
      • Houston, Texas, Stati Uniti, 77204
        • Memorial Hermann Memorial City Digestive Health Center (For Colonoscopy)
      • Pearland, Texas, Stati Uniti, 77584
        • LinQ Research, LLC
      • Tyler, Texas, Stati Uniti, 75701
        • Tyler Research Institute, LLC
      • Tyler, Texas, Stati Uniti, 75701
        • UT Health East Texas Physicians (pulmonary functions only)
      • Tyler, Texas, Stati Uniti, 75701
        • Christus Trinity Mother Frances Endoscopy Center (endoscopies only)
      • Tyler, Texas, Stati Uniti, 75701
        • Heaton Eye Associates (OCT only)
      • Victoria, Texas, Stati Uniti, 77904
        • Victoria Gastroenterology
      • Victoria, Texas, Stati Uniti, 77904
        • Citizens Healthplex (for PFT only)
      • Victoria, Texas, Stati Uniti, 77904
        • Surgery Center (For endoscopy only)
      • Victoria, Texas, Stati Uniti, 77904
        • Victoria Eye Center (For OCT only)
      • Webster, Texas, Stati Uniti, 77598
        • GI Alliance Webster
    • Virginia
      • Forest, Virginia, Stati Uniti, 24551
        • Harman Eye Center (OCT only)
      • Lynchburg, Virginia, Stati Uniti, 24502
        • Blue Ridge Medical Research
      • Lynchburg, Virginia, Stati Uniti, 24501
        • Lynchburg Pulmonary Associates, Inc. (PFT only)
    • Washington
      • Issaquah, Washington, Stati Uniti, 98029
        • Swedish Endoscopy Center - Issaquah
      • Seattle, Washington, Stati Uniti, 98122
        • Swedish Medical Center
      • Seattle, Washington, Stati Uniti, 98104
        • Swedish Gastroenterology
      • Seattle, Washington, Stati Uniti, 98104
        • Pacific Northwest Retina
      • Seattle, Washington, Stati Uniti, 98104
        • Richard Bensinger, MD
      • Seattle, Washington, Stati Uniti, 98122
        • First Hill Endoscopy Center
      • Seattle, Washington, Stati Uniti, 98122
        • Pulmonary Function Lab
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Froedtert Memorial Lutheran Hospital
    • Free State
      • Bloemfontein, Free State, Sud Africa, 9301
        • Dr W Simmonds (Gastroenterology Department)
    • Gauteng
      • Benoni, Gauteng, Sud Africa, 1501
        • Worthwhile Clinical Trials
      • Benoni, Gauteng, Sud Africa, 1500
        • Dr K Rahman (OTC and Opthalmoscopy)
      • Benoni, Gauteng, Sud Africa, 1500
        • Lakeview Hospital radiology (Radiology)
      • Benoni, Gauteng, Sud Africa, 1500
        • Worthwhile Clinical trials (PFT)
      • Centurion, Gauteng, Sud Africa, 0157
        • Dr E Meyer & Partners, Centurion Eye Hospital (OTC and Opthalmoscopy)
      • Centurion, Gauteng, Sud Africa, 0157
        • Dr Jorg Reichenberger (Endoscopy)
      • Centurion, Gauteng, Sud Africa, 0157
        • Drs Burger Radiologists Inc (X-ray/CT)
      • Centurion, Gauteng, Sud Africa, 0157
        • Johese Clinical Research, Unitas Hospital
      • Johannesburg, Gauteng, Sud Africa, 2193
        • Wits Clinical Research
      • Kempton Park, Gauteng, Sud Africa, 1619
        • Clinresco Centres (Pty) Ltd
      • Kempton Park, Gauteng, Sud Africa, 1619
        • Burger Radiology (Radiology)
      • Kempton Park, Gauteng, Sud Africa, 1619
        • Dr KJP Lubuya (OCT and Opthalmology)
      • Kempton Park, Gauteng, Sud Africa, 1619
        • Prof O Mwantembe (Endoscopy)
      • Pretoria, Gauteng, Sud Africa, 0002
        • Emmed Research
      • Springs, Gauteng, Sud Africa, 1559
        • Dr K Rahman(OTC and Opthalmoscopy)
      • Sunninghill, Gauteng, Sud Africa, 2196
        • Dr I Moola (Endoscopy)
    • Western Cape
      • Cape Town, Western Cape, Sud Africa, 7405
        • Dr Peter Chapman (PFT + DLCO)
      • Cape Town, Western Cape, Sud Africa, 7441
        • Dr Chris Stander (OCT)
      • Cape Town, Western Cape, Sud Africa, 7441
        • Morton & Partners Radiologists (Radiology)
      • Cape Town, Western Cape, Sud Africa, 7441
        • Spoke Research Inc. Room 109
      • Bern, Svizzera, 3010
        • Inselspital Bern
      • Bern, Svizzera, 3012
        • OCT/Ophtalmoscopy: Berner Augenklinik am Lindenhofspital
      • Ankara, Turchia (Türkiye), 06500
        • Gazi University Medical Faculty
      • Ankara, Turchia (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Ankara, Turchia (Türkiye), 06800
        • T.C. Saglik Bakanligi Ankara Sehir Hastanesi
      • Antalya, Turchia (Türkiye), 07100
        • Saglik Bilimleri Universitesi Antalya Egitim ve Arastirma Hastanesi
      • Izmir, Turchia (Türkiye), 35100
        • Ege Universitesi Tip Fakultesi Hastanesi
      • Kocaeli, Turchia (Türkiye), 41380
        • Kocaeli University Research and Training Hospital
      • Yenişehir, Turchia (Türkiye), 33343
        • Mersin University Faculty of Medicine
      • Kharkiv, Ucraina, 61124
        • Communal Non-commercial Enterprise City Clinical Hospital #13 of Kharkiv City Council
      • Kharkiv, Ucraina, 61024
        • LLC "EyeQClinic"
      • Kharkiv, Ucraina, 61022
        • Llc "Ldts Skaymed'
      • Kharkiv, Ucraina, 61037
        • Communal Non-commercial Enterprise Prof. O.O. Shalimov City Clinical Hospital #2 of Kharkiv
      • Kharkiv, Ucraina, 61045
        • Llc "Medical Center Oftalmika"
      • Kharkiv, Ucraina, 61103
        • Municipal Health Care "Kharkiv City Hospital Ambulance and Emergency Medical care
      • Kyiv, Ucraina, 01135
        • Medical Center of Limited Liability Company Harmoniia Krasy
      • Kyiv, Ucraina, 02091
        • Med Center 'Ok!Clinic+' of Comp with limited liability "Int Inst of Clin Research", Unit of Gastro
      • Kyiv, Ucraina, 04210
        • Private Enterprise "Clinic Medicom"
      • Lutsk, Ucraina, 43005
        • CE Volyn Reg Clinical Hospital ofVolyn Reg Council, Surgical (Endocrine and Abdominal Pathology)
      • Vinnytsia, Ucraina, 21000
        • Private Enterprise Diagnostic Center "Mediscan"
      • Vinnytsia, Ucraina, 21009
        • Medical Center of LLC Health Clinic, Medical Clinical Research Center, Unit of Gastroenterology,
      • Vinnytsia, Ucraina, 21018
        • CNE of M.I. Pyrohov Vinnytsia Regional Clinical Hospital of Vinnytsia Regional Council, Reg
      • Vinnytsia, Ucraina, 21029
        • Scientific and Research Institute of Invalid Rehabilitation (Educational, Scientific and Treatment
      • Budapest, Ungheria, 1136
        • Pannonia Maganorvosi Centrum
      • Budapest, Ungheria, 1033
        • Clinexpert Egeszsegugyi Szolgaltato es Kereskedelmi Kft. (abbreviated name: Clinexpert Kft.)
      • Budapest, Ungheria, 1062
        • Ophthalmology procedures: Magyar Honvedseg Egeszsegugyi Kozpont
      • Budapest, Ungheria, 1062
        • Pulmonary procedures: Vasutegeszsegugyi Nonprofit Kozhasznu K ft.
      • Budapest, Ungheria, 1134
        • Ophthalmology, OCT: Medicover Zrt.
      • Budapest, Ungheria, 1139
        • Chest X-ray: XIII. keruleti Egeszsegugyi Szolgalat Kozhasznu Nonprofit Kft.
      • Békéscsaba, Ungheria, 5600
        • Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, 4. Belgyogyaszat es 2. Gasztroenterologia
    • Heves County
      • Gyöngyös, Heves County, Ungheria, 3200
        • Bugat Pal Korhaz, Gasztroenterologia
    • Komárom-Esztergom
      • Tatabánya, Komárom-Esztergom, Ungheria, 2800
        • Szent Borbala Korhaz
      • Tatabánya, Komárom-Esztergom, Ungheria, 2800
        • DLCO and ophthalmology tests: Szent Borbala Korhaz

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Descrizione

Criteri di ammissibilità applicabili a tutti i sottostudi:

Criterio di inclusione:

  • Uomini o donne di età compresa tra 18 e 80 anni,
  • Capacità di fornire consenso informato scritto o assenso e di essere conforme al programma delle valutazioni del protocollo
  • Diagnosi di malattia di Crohn (MC) ≥ 3 mesi
  • Avere CD da moderatamente a gravemente attivo allo Screening
  • Risposta inadeguata dimostrata (ossia, non risposta primaria), perdita di risposta o intolleranza a ≥ 1 delle seguenti terapie per il trattamento della CD:

    1. Corticosteroidi orali (p. es., prednisone o suo equivalente, budesonide)
    2. Immunosoppressori (p. es., azatioprina [AZA], 6-mercaptopurina [6-MP] o metotrexato [MTX])
    3. Antagonisti del fattore di necrosi tumorale alfa (TNFα) (p. es., infliximab, adalimumab, certolizumab pegol o biosimilari)
    4. Antagonista del recettore dell'integrina (p. es., vedolizumab)
    5. Antagonista dell'interleuchina -12/-23 (p. es., ustekinumab)
  • Le donne in età fertile devono essere non gravide
  • Le donne in età fertile e gli uomini devono usare la contraccezione

Criteri di esclusione:

  • Anamnesi di risposta inadeguata (ossia, non risposta primaria) ad agenti di ≥ 2 classi di farmaci biologici commercializzati per il trattamento della MC (ossia, antagonisti del TNFα, antagonisti dell'interleuchina 12/23 e antagonisti del recettore dell'integrina).
  • Avere colite ulcerosa, colite indeterminata, colite microscopica, colite ischemica, colite da radiazioni, colite associata a malattia diverticolare, megacolon tossico o colite infettiva attiva o test positivo per la tossina di Clostridioides difficile allo screening.
  • Soffrono di sindrome dell'intestino corto funzionale o postoperatoria o di qualsiasi complicanza associata che possa richiedere un intervento chirurgico o interferire con le valutazioni di efficacia
  • - Ha subito un trattamento chirurgico per ascessi intraaddominali ≤ 8 settimane prima della randomizzazione o un trattamento chirurgico per ascessi perianali ≤ 4 settimane prima della randomizzazione.
  • Aveva una resezione intestinale ≤ 24 settimane prima della randomizzazione o altri interventi chirurgici intraddominali ≤ 12 settimane prima della randomizzazione.
  • Avere una ileostomia o una colostomia.

Criteri di inclusione per il sottostudio 3:

- I partecipanti che sono entrati nel periodo di tirocinio esteso del sottostudio 1 e del sottostudio 2 devono aver completato la visita della settimana 6 di tirocinio esteso

Criteri di inclusione per il sottostudio 4:

- Il partecipante deve aver completato la visita della settimana 52 del sottostudio 3 o la visita della settimana 66 del sottostudio A

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo
Etrasimod compressa placebo corrispondente assunta per via orale, una volta al giorno.
Sperimentale: Etrasimod dose A
Dose A assunta per via orale, una volta al giorno.
Altri nomi:
  • APD334
Dose B assunta per via orale, una volta al giorno.
Altri nomi:
  • APD334
Sperimentale: Etrasimod dose B
Dose A assunta per via orale, una volta al giorno.
Altri nomi:
  • APD334
Dose B assunta per via orale, una volta al giorno.
Altri nomi:
  • APD334

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA
Lasso di tempo: Week 14 of SSA
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from study baseline in SES-CD. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
Week 14 of SSA
Percentage of Participants With Endoscopic Response by SES-CD at Week 14: SS1
Lasso di tempo: Week 14 of SS1
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from study baseline in SES-CD. SES-CD consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple can be passed, 3= cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. Multiple imputation (MI) method used; percentage calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); hematocrit (HCT): 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%,2= 50%-75%,3= >75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right, transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%,2= 50%-75%,3= >75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
Week 52 of study

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With Clinical Remission by CDAI at Week 14: SSA
Lasso di tempo: Week 14 of SSA
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 14 of SSA
Change From Baseline in SES-CD Score at Week 14: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in CDAI Score at Week 14: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Plasma Concentration of Etrasimod at 4 Hours Post-dose: SSA
Lasso di tempo: 4 hours post-dose on Day 1
The plasma concentration of etrasimod at 4 hours post-dose has been reported in this outcome measure.
4 hours post-dose on Day 1
Steady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA
Lasso di tempo: From Week 2 to Week 14
The average steady-state Ctrough for Week 2 through 14 was calculated based on individual Ctrough data from Week 2, Week 6 and Week 14.
From Week 2 to Week 14
Change From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in ALC at Week 14 in Induction Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in ALC at Week 66 in Extension Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in ALC at Week 66 in Extension Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Change From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Change From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in CRP at Week 14 in Induction Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in CRP at Week 66 in Extension Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in CRP at Week 66 in Extension Period: SSA
Lasso di tempo: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percentage of Participants With Clinical Remission by CDAI at Week 14: SS1
Lasso di tempo: Week 14 of SS1
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. MI method was used; percentage was calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS1
Lasso di tempo: Week 14 of SS1
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. MI method was used; percentage was calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Clinical remission was CDAI score <150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Clinical remission was CDAI score <150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= <10%, 2= 10%-30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50%-75%,3= >75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
Week 52 of study
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= <10%, 2= 10%-30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50%-75%,3= >75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
Week 52 of study
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Corticosteroid-free remission: CDAI score <150 without receiving corticosteroids for >=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Corticosteroid-free remission: CDAI score <150 without receiving corticosteroids for >=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Endoscopic remission: SES-CD score <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Endoscopic remission: SES-CD score <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Clinical response: clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
Week 52 of study
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Clinical response: clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
Week 52 of study
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
Lasso di tempo: Baseline, study Weeks 20, 28, 36, 44, 52
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44, 52
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
Lasso di tempo: Baseline, study Weeks 20, 28, 36, 44, 52
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44, 52
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Clinical Response was clinical remission by CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Clinical Response was clinical remission by CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Responder Cohort
Lasso di tempo: Baseline, study Weeks 28 and 52
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Non-Responder Cohort
Lasso di tempo: Baseline, study Weeks 28 and 52
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Weeks 28 and 52: SS3 Responder Cohort
Lasso di tempo: Baseline, study Weeks 28 and 52
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in IBDQ at Weeks 28 and 52: SS3 Non-Responder Cohort
Lasso di tempo: Baseline, study Weeks 28 and 52
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) at Weeks 28 and 52: SS3 Responder Cohort
Lasso di tempo: Baseline, study Weeks 28 and 52
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores mental (MCS) and physical (PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in SF-36 at Weeks 28 and 52: SS3 Non-Responder Cohort
Lasso di tempo: Baseline, study Weeks 28 and 52
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores MCS and PCS. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 28 and 52: SS3 Responder Cohort
Lasso di tempo: Baseline, study Weeks 28 and 52
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in FACIT-F at Weeks 28 and 52: SS3 Non-Responder Cohort
Lasso di tempo: Baseline, study Weeks 28 and 52
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
Lasso di tempo: Baseline, study Weeks 20, 28, 36, 44 and 52
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44 and 52
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
Lasso di tempo: Baseline, study Weeks 20, 28, 36, 44 and 52
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44 and 52
Time to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort
Lasso di tempo: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score <8. Normalization of FCP was defined as FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
Lasso di tempo: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score <8. Normalization of FCP was defined as FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort
Lasso di tempo: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or >= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score <8. Normalization of FCP: FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
Lasso di tempo: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or >= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score <8. Normalization of FCP: FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Change From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort
Lasso di tempo: Baseline and Week 52 of study
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0=unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline and Week 52 of study
Change From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort
Lasso di tempo: Baseline and Week 52 of study
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0=unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline and Week 52 of study
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Lasso di tempo: Week 52 of study
Endoscopic remission: SES-CD <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Lasso di tempo: Week 52 of study
Endoscopic remission: SES-CD <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Number of Participants According to Markedly Abnormal Criteria for Electrocardiogram (ECG) Parameters: SS4
Lasso di tempo: Baseline, Weeks 52, and 104 of SS4
Pre-defined markedly abnormal criteria for ECG parameters included: QT interval: >500 (milliseconds [msec]); change from SS4 baseline >30 msec and change from SS4 baseline >60 msec. QT interval corrected using Fridericia's formula (QTcF) (msec): >=450 (male) or >=470 (female) msec; change from SS4 baseline >30 msec; change from SS4 baseline >60 msec. PR interval (msec): >230 msec. Only those ECG parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 Baseline was defined as the last non-missing measurement taken up to the date of first dose in the SS4.
Baseline, Weeks 52, and 104 of SS4
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs by Severity and Treatment Related TEAEs: SS3
Lasso di tempo: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, Grade(G) 1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With TEAEs of Special Interest: SS3
Lasso di tempo: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
The TEAEs of special interest included: cardiovascular events (bradycardia, atrioventricular [AV] conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction [forced expiratory volume in 1 second, and forced vital capacity], decreased gas exchange [diffusing capacity of the lung for carbon monoxide]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS3
Lasso di tempo: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (<0.8*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration <0.8*LLN or >1.5*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (>1.2*ULN), Prothrombin Time(>1.1*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (>3.0*ULN); Albumin, Urate (<0.8*LLN and >1.2*ULN; Urea Nitrogen,Creatinine Cholesterol >1.3*ULN; Cholesterol <0.8*LLN or >1.2*LLN, Triglycerides,Potassium,Calcium < 0.9x LLN & >1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite >=1; Leukocyte Erythrocytes, Leukocytes >=20; Epithelial Cells>=6, Hyaline Cast>1; Bacteria>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With TEAEs, SAEs, TEAEs by Severity and Treatment Related TEAEs: SS4
Lasso di tempo: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, G1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants With TEAEs of Special Interest: SS4
Lasso di tempo: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
The TEAEs of special interest included: cardiovascular events (bradycardia, AV conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction [forced expiratory volume in 1 second, and forced vital capacity], decreased gas exchange [diffusing capacity of the lung for carbon monoxide]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS4
Lasso di tempo: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (<0.8*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration <0.8*LLN or >1.5*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (>1.2*ULN), Prothrombin Time(>1.1*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (>3.0*ULN); Albumin, Urate (<0.8*LLN and >1.2*ULN; Urea Nitrogen,Creatinine Cholesterol >1.3*ULN; Cholesterol <0.8*LLN or >1.2*LLN, Triglycerides,Potassium,Calcium < 0.9x LLN & >1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite >=1; Leukocyte Erythrocytes, Leukocytes >=20; Epithelial Cells>=6, Hyaline Cast>1; Bacteria>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants According to Markedly Abnormal Criteria for Vital Signs: SS4
Lasso di tempo: Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Pre-defined markedly abnormal criteria for vital signs included: Systolic blood pressure (millimeters of mercury [mmHg]): low: <=90 mmHg and high: >150 mmHg. Diastolic blood pressure (mmHg): low: <=50 mmHg and high: >90 mmHg. Heart rate (beats per minute [bpm]): low: <40 bpm, <50 bpm and high: >100 bpm. Only those vital signs parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 baseline=the last non-missing measurement taken up to the date of first dose in the SS4.
Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Remission by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Lasso di tempo: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Response by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Lasso di tempo: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical Response was defined as having clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission was considered as CDAI <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Remission by PRO2 at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Lasso di tempo: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Direttore dello studio: Pfizer CT.gov Call Center, Pfizer

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

6 gennaio 2020

Completamento primario (Effettivo)

23 aprile 2025

Completamento dello studio (Effettivo)

9 giugno 2025

Date di iscrizione allo studio

Primo inviato

20 novembre 2019

Primo inviato che soddisfa i criteri di controllo qualità

20 novembre 2019

Primo Inserito (Effettivo)

21 novembre 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • APD334-202
  • C5041006 (Altro identificatore: Alias Study Number)
  • 2024-513569-38-00 (Identificatore di registro: CTIS (EU))

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Pfizer fornirà l'accesso ai dati dei singoli partecipanti anonimi e ai relativi documenti di studio (ad es. protocollo, piano di analisi statistica (SAP), rapporto di studio clinico (CSR)) su richiesta di ricercatori qualificati e soggetti a determinati criteri, condizioni ed eccezioni. Ulteriori dettagli sui criteri di condivisione dei dati di Pfizer e sul processo di richiesta di accesso sono disponibili all'indirizzo: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .